Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 15/20 | 0.58 |
| ▸ | MMP3 | P08254 | 11/20 | 0.58 |
| ▸ | MMP2 | P08253 | 11/20 | 0.58 |
| ▸ | MMP9 | P14780 | 7/20 | 0.58 |
| ▸ | MMP7 | P09237 | 6/20 | 0.58 |
| ▸ | MMP14 | P50281 | 3/20 | 0.58 |
| ▸ | MME | P08473 | 1/20 | 0.51 |
| ▸ | MMP8 | P22894 | 4/20 | 0.48 |
| ▸ | FCER2 | P06734 | 1/20 | 0.48 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7427129 | 1.00 | MMP1 (0.58) | MMP1MMP3MMP2MMP9MMP7 | |
| SCHEMBL7898741 | 1.00 | MMP1 (0.58) | MMP1MMP3MMP2MMP9MMP7 | |
| SCHEMBL6415164 | 1.00 | MMP1 (0.58) | MMP1MMP3MMP2MMP9MMP7 | |
| SCHEMBL8764329 | 0.97 | MMP1 (0.58) | MMP1MMP3MMP2MMP9MMP7 | |
| SCHEMBL6416194 | 0.97 | MMP1 (0.58) | MMP1MMP3MMP2MMP9MMP7 | |
| SCHEMBL7381282 | 0.97 | MMP1 (0.58) | MMP1MMP3MMP2MMP9MMP7 | |
| SCHEMBL6846260 | 0.94 | MMP1 (0.56) | MMP1MMP3MMP2MMP9MMP7 | |
| SCHEMBL7424545 | 0.94 | MMP1 (0.56) | MMP1MMP3MMP2MMP9MMP7 | |
| SCHEMBL7383987 | 0.94 | MMP1 (0.56) | MMP1MMP3MMP2MMP9MMP7 | |
| SCHEMBL6416229 | 0.94 | MMP1 (0.56) | MMP1MMP3MMP2MMP9MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | disclosed |
| EP-1063991-A1 | STATIN-MATRIX METALLOPROTEINASE INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY LLC (US) | 2001-01-03 | — | — | EP | disclosed |
| EP-1047450-A1 | ACE INHIBITOR-MMP INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 2000-11-02 | — | — | EP | disclosed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | disclosed |
| EP-0946166-A1 | USE OF MATRIX METALLOPROTEINASE INHIBITORS FOR TREATING NEUROLOGICAL DISORDERS AND PROMOTING WOUND HEALING | WARNER-LAMBERT COMPANY (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1999047138-A1 | STATIN-MATRIX METALLOPROTEINASE INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 1999-09-23 | — | — | WO | disclosed |
| WO-1999032150-A1 | ACE INHIBITOR-MMP INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 1999-07-01 | — | — | WO | disclosed |
| WO-1998026773-A1 | USE OF MATRIX METALLOPROTEINASE INHIBITORS FOR TREATING NEUROLOGICAL DISORDERS AND PROMOTING WOUND HEALING | WARNER-LAMBERT COMPANY (US) | 1998-06-25 | — | — | WO | disclosed |